Correction: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy | Synapse
March 3, 2026Open Access
Correction: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
Key Points
Overall survival is influenced by the risk of checkpoint immune pneumonitis in non-small cell lung cancer patients.
The article provides a correction to previously reported findings regarding patient outcomes.
Assessment of overall survival metrics indicates important implications for patient treatment strategies.
Understanding risk factors may enhance treatment planning for lung cancer therapies.
Abstract
This corrects the article DOI: 10.3389/fonc.2020.570233..